Join to View Full Profile
1500 E Medical Center DrAnn Arbor, MI 48109
Phone+1 734-936-4000
Dr. Shahinian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Medical Branch HospitalsFellowship, Nephrology, 1997 - 1999
Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
University of Toronto Faculty of MedicineClass of 1994
Certifications & Licensure
MI State Medical License 2006 - 2025
FL State Medical License 2009 - 2014
TX State Medical License 2002 - 2007
American Board of Internal Medicine Nephrology
Publications & Presentations
PubMed
- Skilled Nursing Facility Utilization Among Community-Dwelling Older Adults With Alzheimer's Disease and Related Dementias During the COVID-19 Pandemic.Meiling Ying, Zijing Cheng, Richard A Hirth, Brent K Hollenbeck, Karen E Joynt Maddox
Journal of the American Medical Directors Association. 2025-03-17 - Early Effects of Pathways to Success on Utilization in Traditional Medicare.Meiling Ying, Addison Shay, John M Hollingsworth, Vahakn B Shahinian, Brent K Hollenbeck
Health Services Research. 2025-03-13 - Spillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer.Arnav Srivastava, Samuel R Kaufman, Xiu Liu, Avinash Maganty, Addison Shay
Cancer Medicine. 2025-03-01
Press Mentions
Can Financial Incentives Boost Active Surveillance Rates for Low-Risk Prostate Cancer?January 9th, 2025
Prostate Cancer Hormonal Therapy Tied to Kidney RisksJuly 31st, 2013
Prostate Cancer Hormonal Therapy Tied to Kidney RisksJuly 16th, 2013- Join now to see all
Grant Support
- Urology practice consolidation and care for men with prostate cancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2029
- Urology practice consolidation and care for men with prostate cancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Advanced Training in Urologic OncologyUNIVERSITY OF MICHIGAN AT ANN ARBOR2014–2029
- Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patientsUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2028
- Leveraging the ESRD Treatment Choices model to understand the benefits of home versus in-center dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Effects of integration of advanced practice providers into surgical group practiceUNIVERSITY OF MICHIGAN AT ANN ARBOR2023–2027
- Aligning financial incentives to promote rational use of active surveillance for prostate cancerUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2027
- Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancerUNIVERSITY OF MISSOURI-COLUMBIA2024–2026
- Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancerUNIVERSITY OF MISSOURI-COLUMBIA2024–2026
- Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancerUNIVERSITY OF MISSOURI-COLUMBIA2024–2026
- Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancerUNIVERSITY OF MISSOURI-COLUMBIA2024–2026
- Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancerUNIVERSITY OF MISSOURI-COLUMBIA2024–2026
- Planning to implement high-quality active surveillance in new-onset favorable risk prostate cancerUNIVERSITY OF MISSOURI-COLUMBIA2024–2026
- Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Real-world effectiveness of preventive pharmacological therapy for patients with kidney stonesUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Real-world effectiveness of preventive pharmacological therapy for patients with kidney stonesUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Real-world effectiveness of preventive pharmacological therapy for patients with kidney stonesUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Real-world effectiveness of preventive pharmacological therapy for patients with kidney stonesUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Real-world effectiveness of preventive pharmacological therapy for patients with kidney stonesUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Real-world effectiveness of preventive pharmacological therapy for patients with kidney stonesUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Primary care involvement in End Stage Renal Disease Seamless Care Organizations (ESCOs) and the quality and costs of care for patients on chronic dialysisUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025
- Optimizing Use Of Androgen Deprivation Therapy For Prostate CancerNational Cancer Institute2009–2010
- GNRH Agonists For Prostate Cancer: Role Of The UrologistNational Cancer Institute2006–2007
- GNRH Agonists For Prostate Cancer: Role Of The UrologistNational Cancer Institute2005–2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
